SEARCH

SEARCH BY CITATION

References

  • 1
    Hönigsmann H, Szeimis R-M, Knobler R, et al. Photochemotherapy and photodynamic therapy. In Fitzpatrick's Dermatology in General Medicine, eds. FreedbergIM, EisenAZ, WolffK, et al. New York: McGraw-Hill, 1999: 28802900.
  • 2
    Stern RS, Laird N. The carcinogenic risk of treatment for severe psoriasis. Cancer 1994; 73: 27592764.
  • 3
    Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 10411045.
  • 4
    De Rie MA, Van Eendenburg JP, Versnick AC, et al. A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema. Br J Dermatol 1995; 132: 964969.
  • 5
    Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol 1976; 56: 383390.
  • 6
    Grundmann-Kollmann M, Tegeder I, Ochsendorf FR, et al. Kinetics and dose–response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical aplication of three standard preparations. Br J Dermatol 2001; 144: 991995.
  • 7
    Lüftl M, Degitz K, Plewig G, et al. Psoralen bath plus UV-A therapy. Possibilities and limitations. Arch Dermatol 1997; 133: 15971603.
  • 8
    Stege H, Berneburg M, Ruzicka T, et al. Creme-PUVA-photochemotherapie. Hautarzt 1997; 48: 8993.
  • 9
    Collins P, Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 1992; 127: 392395.
  • 10
    Herfst MJ, De Wolff FA. Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients. Clin Pharmacol Ther 1983; 34: 117124.
  • 11
    Yeo UC, Shin JH, Yang JM, et al. Psoralen-ultraviolet A-induced erythema: sensitivity correlates with the concentrations in suction blister fluid. Br J Dermatol 2000; 142: 733739.
  • 12
    McLelland J, Fisher C, Farr PM, et al. The relationship between plasma psoralen concentration and psoralen-UVA erythema. Br J Dermatol 1991; 124: 585590.
  • 13
    De Wolff FA, T Homas TV. Clinical pharmacokinetics of metholxsalen and other psoralens. Clin Pharmacokinet 1986; 11: 6275.
  • 14
    Beani JC, Sarrazin C, Amblard P, et al. Comparison between plasma levels of 8-methoxypsoralen and skin photosensitivity: the interest of pharmacokinetic studies during photochemotherapy of psoriasis. Dermatologica 1983; 166: 169174.
  • 15
    Calzavara-Pinton PG, Ortel B, Carlino AM, et al. Phototesting and phototoxic side effects in bath PUVA. J Am Acad Dermatol 1993; 28: 657659.
  • 16
    Hönigsmann H, Jaschke E, Nitsche V, et al. Serum levels of 8-methoxsypsoralen in two different drug preparations: correlation with photosensitivity and UV-A dose requirements for photochemotherapy. J Invest Dermatol 1982; 79: 233236.
  • 17
    Tegeder I, Bräutigam L, Podda M, et al. Time course of 8-methoxaypsoralen concentrations in skin and plasma following oral, bath and cream PUVA therapy. Clin Pharmacol Ther in press.
  • 18
    Grundmann-Kollmann M, Ochsendorf F, Zollner TM, et al. PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000; 43: 675678.
  • 19
    Podda M, Rallis M, Traber MG, et al. Kinetic study of cutaneous and subcutaneous distribution following topical application of [7,8–14C]rac-alpha-lipoic acid onto hairless mice. Biochem Pharmacol 1996; 52: 627633.
  • 20
    Goldsmith LA. Physiology, Biochemistry and Molecular Biology of the skin. Oxford: Oxford University Press, 1991.
  • 21
    Grundmann-Kollmann M, Leiter U, Behrens S, et al. The time course of phototoxicity of topical PUVA. 8-methoxypsoralen cream-PUVA vs. 8-methoxypsoralen gel-PUVA. Br J Dermatol 1999; 140: 988990.
  • 22
    Kammerau B, Klebe U, Zesch A, et al. Penetration, permeation, and resorption of 8-methoxypsoralen. Comparative in vitro and in vivo studies after topical application of four standard preparations. Arch Dermatol Res 1976; 255: 3142.
  • 23
    Neumann NJ, Grosse O, Ruzicka T, et al. Penetration kinetics of 8-methoxypsoralen after 8-methoxypsoralen bath procedure with and without UVA irradiation. Skin Pharmacol Appl Skin Physiol 2001; 14: 210216.
  • 24
    Degitz K, Plewig G, Röcken M. Rapid decline in photosensitivity after 8-methoxypsoralen bathwater delivery. Arch Dermatol 1996; 132: 13941395.
  • 25
    Kerscher M, Gruss C, Von Kobyletzki G, et al. Time course of 8-MOP-induced skin photosensitization in PUVA bath photochemotherapy. Br J Dermatol 1997; 136: 473474.
  • 26
    Ogawa H, Yoshike T. Atopic dermatitis: studies of skin permeability and effectiveness of topical PUVA treatment. Pediatr Dermatol 1992; 9: 383385.
  • 27
    Von Kobeletzki G, Hoffmann K, Kerscher M, et al. Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy. Photodermatol Photoimmunol Photomed 1998; 14: 136138.